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In colorectal neoplasms, N-myc downstream-regulated gene 1 (NDRG1) is a primarily cytoplasmic pro-
tein, but it is also expressed on the cell membrane and in the nucleus. NDRG1 is involved in various stages
of tumor development in colorectal cancer, and it is possible that the different subcellular localizations
may determine the function of NDRG1 protein. Here, we attempt to clarify the characteristics of NDRG1
protein subcellular localization during the progression of colorectal cancer. We examined NDRG1 expres-
sion in 49 colorectal cancer patients in cancerous, non-cancerous, and corresponding lymph node tissues.
Cytoplasmic and membrane NDRG1 expression was higher in the lymph nodes with metastases than in
those without metastases (P < 0.01). Nuclear NDRG1 expression in colorectal neoplasms was signiﬁcantly
higher than in the normal colorectal mucosa, and yet the normal colorectal mucosa showed no nuclear
expression. Furthermore, our results showed higher cytoplasmic NDRG1 expression was better for differ-
entiation, and higher membrane NDRG1 expression resulted in a greater possibility of lymph node metas-
tasis. These data indicate that a certain relationship between the cytoplasmic and membrane expression
of NDRG1 in lymph nodes exists with lymph node metastasis. NDRG1 expression may translocate from
the membrane of the colorectal cancer cells to the nucleus, where it is involved in lymph node metastasis.
Combination analysis of NDRG1 subcellular expression and clinical variables will help predict the inci-
dence of lymph node metastasis.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license. 1. IntroductionColorectal cancer is the third most commonly diagnosed cancer
in males and the second in females, and over 1.2 million new can-
cer cases and 608,700 deaths occurred from colorectal cancer in
2008 [1]. Despite advances in surgical and nonsurgical therapies,
colorectal tumors are still the third major cause of cancer-related
mortality [2]. Traditional therapies have focused on treating the
symptoms and not the cause of the disease. Thus, new treatments
for colorectal cancer have focused on the important molecules in-
volved in disease progression.
N-myc downstream-regulated gene 1 (NDRG1), also known as
Drg1, Cap43, RTP, Rit42, and PROXY-1, is a member of the NDRGgene family. NDRG1 is a highly conserved protein between mouse
and human, and it is comprised of a 394 amino acid polypeptide,
with a molecular weight of 43 kDa [3,4]. NDRG1 is a multifunc-
tional protein involved in tumorigenesis and tumor development,
and its function differs in different tumor types. In colorectal, pros-
tate, cervical, and ovarian cancers, NDRG1 plays important roles in
metastasis suppression [5–8], while in hepatocellular carcinomas,
NDRG1 enhances portal vein invasion and intrahepatic metastasis
[9,10]. NDRG1 expression has been correlated with various clinico-
pathological features, such as histopathological type, tumor differ-
entiation, Dukes’ stage, lymphatic invasion, and venous invasion,
but these correlations may depend on the race or ethnicity of the
patients [11–13]. NDRG1 has long been deﬁned as a metastasis
suppressor gene in colorectal cancer. Numerous clinical and scien-
tiﬁc studies have explored the possible mechanisms by which
NDRG1 inhibits metastasis.
Recently, more and more studies have focused on the correla-
tion between the subcellular localization of molecules and tumor
development. Generally, these molecules perform different
functions depending on their subcellular localization. SIRT1, a
well-studied protein that has different subcellular localizations,
Table 1
Characteristics of the study population.
Categorical variables n = 49 (%)
Sex
Female 20 (40.8)
Male 29 (59.1)
Age
Mean ± SD 54.3 ± 13.1
Tumor distribution
Rectum 25 (51.0)
Colon 24 (49.0)
Pathological grading
II 16 (32.7)
II–III 10 (20.4)
III 23 (46.9)
Lymph node metastasis
Yes (N1 + N2) 37 (75.5)
No (N0) 12 (24.5)
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negative effects on carcinogenesis partially due to its subcellular
localization. The nuclear or cytoplasmic localization of SIRT1 af-
fected its substrate speciﬁcity in both normal and cancer cells.
Furjelova et al. clariﬁed the signiﬁcant differences of CA IX
expression that depend on subcellular localization in ﬁbroadeno-
mas and carcinomas; they conﬁrmed that CA IX was a valuable
biomarker for diagnosis and prognosis determination in breast
cancer [15]. Sun et al. reported that nuclear and cytoplasmic
HuR expression were correlated with different adverse pheno-
types in Gallbladder carcinoma, and cytoplasmic HuR expression
is an independent prognostic factor for poor disease-free survival
[16]. In colorectal cancer, NDRG1 protein is expressed in the cyto-
plasm, on the membrane, and in the nucleus [17–19]. However,
clinical data clarifying the changes of NDRG1 subcellular distribu-
tion during the progression of colorectal cancer are rare. Different
subcellular localization in normal cells, cancer cells, and meta-
static cells may determine the function of NDRG1 protein. Here,
we explored NDRG1 subcellular expression in normal colorectal
mucosa, primary colorectal neoplasms, and metastatic sites in
the regional lymph nodes.Fig. 1. Immunohistochemical staining of NDRG1 in human colorectal tissues. (A–C), repr
images of lymph node samples with metastases. (A and D) Expression of NDRG1 in norma
and F) Expression of NDRG1 in the corresponding regional lymph nodes.2. Materials and methods
2.1. Tissue samples
The tissue microarray was purchased from Shanghai Outdo
Biotech Co., LTD, Shanghai, China and included 49 colorectal
cancer specimens of cancerous, non-cancerous, and correspond-
ing lymph node tissues. Among them, 37 cases were diagnosed
as positive lymph node metastases, and 12 cases were negative.
Table 1 describes the patient characteristics of the study
population.2.2. Immunohistochemistry
Immunohistochemical (IHC) staining was performed directly
on the tissue microarray. NDRG1 goat polyclonal antibody
(Pierce, Thermo Fisher Scientiﬁc, USA) was used at a 1:100 ﬁnal
dilution. Brieﬂy, the slides were treated with 3% H2O2 for
15 min to block endogenous peroxidase activity. Then, the slides
were incubated with 10% normal goat serum to block nonspeciﬁc
binding sites. Thereafter, the slides were incubated with the
primary antibody overnight at 4 C. After washing, peroxidase-
conjugated Afﬁnipure rabbit anti-goat IgG (ZSGB-Bio, China)
was applied at a 1:1000 dilution for 10 min at 37 C. S-P complex
was added at room temperature for 30 min, and diaminobenzi-
dine was used as the ﬁnal chromogen. Finally, the slides were
counterstained with hematoxylin. All of the immunohistochemi-
cal images were captured using an Aperio pathological scanning
system.
Immunoreactivity for NDRG1 expression was independently
assessed by two well-known pathologists from Shanghai Outdo
Biotech Company. Patients who died or did not follow up were
excluded from this study. In total, 41 cases were adopted in
our study. The cell staining reaction was estimated according
to the revolutionary immunoreactive score (IRS) method:
IRS = SI (staining intensity)  PP (percentage of positive cells).
SI was determined as 0 (negative), 1 (weak), 2 (moderate),
or 3 (strong). PP was deﬁned as the exact percentage of positive
cells.esentative images of lymph node samples without metastases. (D–F), representative
l colorectal mucosa. (B and E) Expression of NDRG1 in primary colorectal cancers. (C
Fig. 2. Cytoplasmic NDRG1 expression in the different groups. (A) NDRG1 expres-
sion was signiﬁcantly higher in the colorectal neoplasms than in the lymph nodes
with metastases (P < 0.01). (B) NDRG1 expression was signiﬁcantly higher in the
colorectal neoplasms than in the lymph nodes without metastases (P < 0.01). (C)
NDRG1 expression in the lymph nodes with metastases was higher than in the
lymph nodes without metastases (P < 0.01). ⁄P value <0.05, ⁄⁄P value <0.01.
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The SPSS 19.0 software was used for the statistical analyses. Dif-
ferences in NDRG1 expression between the different groups were
compared using a rank sum test. Spearman’s correlation coefﬁcient
analysis was used to evaluate the relationship between NDRG1
expression and the clinical variables. All reported P values were
two-sided, and P < 0.01 or P < 0.05 was considered statistically
signiﬁcant.3. Results
3.1. NDRG1 expression in the cytoplasm of colorectal cancer cells
Immunoreactivity was primarily observed in the cytoplasm.
Colorectal cancer, adjacent normal colorectal mucosa, and the cor-
responding regional lymph nodes were all positive for cytoplasmic
NDRG1 (Fig. 1). NDRG1 expression was signiﬁcantly higher in the
primary colorectal neoplasms than in the regional lymph nodes
with (P < 0.01; Fig. 2A) or without metastases (P < 0.01; Fig. 2B),
and the expression of NDRG1 in the lymph nodes with metastases
was higher than in those without metastases (P < 0.01; Fig. 2C).
Furthermore, in the patients with lymph nodes metastases, there
was a negative correlation between lymph node staining andhistopathological grading (P < 0.01; rs = 0.401; Fig. 3A). In other
words, higher levels of NDRG1 protein expression in the positive
lymph nodes correlated with the differentiation of the colorectal
neoplasm.
3.2. NDRG1 expression in the membrane of colorectal cancer cells
There was a signiﬁcantly lower expression in the membrane of
the colorectal neoplasms than in the normal colorectal mucosa
(P < 0.01; Fig. 4A and B) and in the patients without lymph nodes
metastases. NDRG1 membrane expression in the colorectal neo-
plasms was higher than in the metastatic lymph nodes (P < 0.01;
Fig. 4B). As in the cytoplasm, NDRG1 membrane expression was
also higher in the lymph nodes with metastases than in those with-
out metastases (P < 0.01; Fig. 4C). It is worth mentioning that there
was no positive staining in the membrane of lymph nodes without
metastasis. In the group with lymph node metastases, there was a
good correlation between cytoplasmic NDRG1 expression in the
colorectal neoplasms and the membrane expression in the lymph
nodes (P < 0.05; rs = 0.402; Fig. 3B), and NDRG1 membrane expres-
sion in the lymph nodes was positively correlated with TNM clas-
siﬁcation (P < 0.05; rs = 0.446; Fig. 3C) and the proportion of
positive lymph nodes (P < 0.05; rs = 0.395; Fig. 3D).
3.3. NDRG1 expression in the nucleus of colorectal cancer cells
There was no observed staining in the nucleus of normal colo-
rectal mucosa or colorectal neoplasms. In the corresponding regio-
nal lymph nodes, the immunoreactivity was relatively weaker than
that of the cytoplasm and the membrane. In the group with lymph
node metastases, nuclear NDRG1 expression in the colorectal neo-
plasms was signiﬁcantly higher than in the normal colorectal mu-
cosa (P < 0.01; Fig. 4D).4. Discussion
NDRG1 is a predominantly cytoplasmic protein, but it is also ex-
pressed in the cell membrane and nucleus. In the cytoplasm,
NDRG1 protein immunoreactivity was localized to the inner mem-
brane of the mitochondria, even though it lacks a mitochondrial
targeting sequence. However, the single phosphopantetheine
attachment site motif may help NDRG1 protein localize in the
mitochondria [19]. NDRG1 was also found to be adjacent to the
adherens junctions and desmosomes within the cytoplasm. There
is a highly hydrophobic 20 amino acid sequence in the NDRG1 pro-
tein sequence that may explain its behavior as a membrane-asso-
ciated protein [20]. Other studies found that NDRG1 expression
was localized in the nucleolus [19]. However, there were no nucle-
ar targeting sequences identiﬁed in the NDRG1 protein sequence.
Cytoplasmic NDRG1 expression was higher in the primary colo-
rectal neoplasms than in the regional lymph nodes with metasta-
ses in this study; these data were in accordance with an in vitro
study that reported that NDRG1 expression was much higher in
SW480 cells (established from a primary colorectal tumor) than
in SW620 cells (established from a lymph node metastasis from
the same patient a year later) [5]. The results of that study indi-
cated that NDRG1 downregulation in SW620 cells was associated
with a decrease in unique histone modiﬁcations. This was also
the case in the patients without lymph nodes metastases. Thus, it
is possible that NDRG1 downregulation in the corresponding
lymph node tissues was not directly correlated with the tumor
metastasis ability. However, cytoplasmic NDRG1 expression in
lymph nodes with metastases was higher than in those without
metastases, which is in agreement with earlier studies [18]. Other
reports have supported the idea that NDRG1 is a metastasis
Fig. 3. Spearman’s correlation coefﬁcient analysis of the lymph nodes with metastasis group. (A) Negative correlation between lymph node staining and histopathological
grading (P < 0.01; rs = 0.401). (B) Positive correlation between cytoplasmic NDRG1 expression in the colorectal cancer tissues and membrane expression in the lymph nodes
(P < 0.05; rs = 0.402). (C) Positive correlation between NDRG1 membrane expression in the lymph nodes and TNM classiﬁcation (P < 0.05; rs = 0.446). (D) Positive correlation
between NDRG1 membrane expression in the lymph nodes and the proportion of positive lymph nodes (P < 0.05; rs = 0.395).
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tween the cytoplasm expression of NDRG1 in lymph nodes and
the probability of lymph node metastasis. NDRG1 inhibited metas-
tasis in colon cancer by preventing actin-ﬁlament polymerization
and stress ﬁber assembly and formation in the cytoplasm [21]. Per-
haps NDRG1 expression in the lymph nodes with metastases plays
a role in inhibiting tumor cells from forming distant metastases. In
the lymph nodes metastases group, higher cytoplasmic NDRG1
expression correlated with better differentiation. NDRG1 has been
shown to induce morphological changes consistent with differenti-
ation and to up-regulate the expression of several epithelial cell
differentiation markers [22]. Therefore, NDRG1 may suppress
metastasis by inducing colorectal cancer cell differentiation and
by partially reversing the metastatic phenotype.
NDRG1 can maintain membrane E-cadherin and b-catenin and
inhibit TGF-b-stimulated cell migration and invasion [23]. Our re-
sults showed that NDRG1 membrane expression was signiﬁcantly
lower in the primary colorectal tumors than in normal colorectal
mucosa, which may indicate that membrane expressed NDRG1
might inhibit the development and progression of colorectal can-
cer. Our results also showed that there was a signiﬁcantly higher
membrane NDRG1 expression in the lymph nodes with metastases
than in those without metastases. Furthermore, in the lymph
nodes metastases group, NDRG1 membrane expression increased
the possibility of lymph node metastases, and NDRG1 membrane
expression was positively correlated with TNM classiﬁcation and
the proportion of positive lymph nodes. These results indicate thatmembrane NDRG1 expression in lymph nodes is involved in lymph
nodes metastasis.
In the lymph nodes metastases group, nuclear NDRG1 expres-
sion was higher in the colorectal cancer tissues than in the normal
colorectal mucosa. In fact, there was no nuclear NDRG1 expression
in normal colorectal mucosa. However, in the lymph nodes metas-
tasis group, the membrane expression was lower in the colorectal
cancer tissues than in the normal colorectal mucosa. Thus, we pro-
pose that NDRG1 expression may translocate from the membrane
of the colorectal cancer tissue into the nucleus where it is involved
in lymph nodes metastasis. However, few studies have focused on
nuclear NDRG1 expression. Prior studies have reported that
NDRG1 could translocate to the nucleus after DNA damage [24],
and these data indicate that NDRG1 might be involved in DNA re-
pair and proper DNA replication.
In summary, it appears that the differences in NDRG1 subcellu-
lar localization in normal colorectal mucosa, colorectal cancer tis-
sues, and corresponding lymph nodes may affect the function of
NDRG1 protein and may determine the probability of lymph nodes
metastasis. For an individual patient, a combined analysis of
NDRG1 subcellular expression in cancerous, non-cancerous, and
corresponding lymph node tissues as well as the clinical variables
will help predict the incidence of lymph node metastasis. The
detection and analysis of NDRG1 subcellular localization in a larger
sample group will further validate our conclusions and clarify the
role of NDRG1 subcellular localization in predicting the occurrence
of lymph nodes metastasis.
Fig. 4. NDRG1 membrane and nuclear expression in the different groups. (A) NDRG1 expression was higher in the normal mucosa than in the lymph nodes with metastases
(P < 0.01). (B) NDRG1 expression was higher in the normal mucosa than in the colorectal cancer in the group of lymph nodes with metastases (P < 0.01) and NDRG1
expression was higher in the colorectal cancer than that in the lymph nodes without metastases (P < 0.01). (C) NDRG1 expression in the lymph nodes with metastases was
higher than in the lymph nodes without metastases (P < 0.01). (D) NDRG1 expression in the normal mucosa was lower than that in the colorectal cancer in lymph nodes
metastasis group (P < 0.01). (E) No signiﬁcant difference was observed in lymph nodes without metastasis group. (F) No signiﬁcant difference was observed between lymph
nodes with and without metastases. ⁄P value <0.05, ⁄⁄P value <0.01.
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